Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Taselisib and fulvestrant fall short in advanced ER+/HER2- breast cancer

Baselga et al. ASCO Abstract LBA1006.

Key clinical point: The PI3K inhibitor taselisib added to fulvestrant offered only modest benefit and significant toxicities in patients with advanced ER+/HER2- breast cancer.

Major finding: The combination of taselisib/fulvestrant extend median progression-free survival by two months.

Study details: Phase 3 randomized trial in 516 women with locally advanced or metastatic ER+/HER2- breast cancer.

Disclosures: The study was funded by F. Hoffman La-Roche. Dr. Baselga had disclosures related to GRAIL, Lilly, and Novartis, Infinity Pharmaceuticals, and Varian Medical Systems, PMV Pharma, and Juno Therapeutics. Dr. Burstein disclosed institutional research funding and speaker’s bureau activities for Novartis. Dr. Ma reported no relevant disclosures.

Source: Baselga et al. ASCO Abstract LBA1006.

Read the article.


Baselga et al. ASCO Abstract LBA1006.

This Week's Must Reads

First-line avelumab/axitinib for RCC benefits wide range of patients, Choueiri TK et al. GUCS 2019, Abstract 544.

Inadequate emergency care a challenge for rural pediatric patients, Walling EB et al. J Oncol Pract. 2019 Jan 31. doi: 10.1200/JOP.18.00115.

QC measures improve with CMS Oncology Care Model, Rocque G et al. J Oncol Pract. 2019. doi: 10. 1200/JOP.18.00390.

Must Reads in Breast Cancer

Therapeutic drug monitoring for tamoxifen not justified, Sanchez-Spitman A et al. J Clin Oncol. 2019 Jan 24. doi: 10.1200/JCO.18.00307.

With a positive sentinel node, RT better than surgery, Rutgers EJT et al. SABCS 2018, Abstract GS4-01

Ten years of anastrozole boosts disease-free survival, Ohtani S et al. SABCS 2018, Abstract GS3-04

Advanced age not linked with risk from nipple-sparing mastectomy, Cox S et al. and Bartholomew AJ et al. Session SF310 ACS Clinical Congress 2018